Although healthcare shares such as Monash IVF Group Ltd (ASX: MVF) and Healthscope Ltd (ASX: HSO) are finding growth hard to come by, this certainly isn’t the case for all shares in the sector. The three shares listed below are growing at a very strong rate at present. I believe this could make them worth a closer look. Here’s why: Nanosonics Ltd (ASX: NAN) In FY 2017 this infection control specialist posted a 56% increase in gross profit thanks largely to strong demand for its trophon EPR system in the United States. As of the end of FY 2017 the…
To keep reading, enter your email address or login below.
The three shares listed below are growing at a very strong rate at present. I believe this could make them worth a closer look. Here’s why:
Nanosonics Ltd (ASX: NAN)
In FY 2017 this infection control specialist posted a 56% increase in gross profit thanks largely to strong demand for its trophon EPR system in the United States. As of the end of FY 2017 the trophon product’s installed base had grown to 14,100 units globally. This equates to just under 12% of its estimated global market opportunity of 120,000 units. I think this is a sign that there’s still plenty more growth left in the tank for Nanosonics.
National Veterinary Care Ltd (ASX: NVL)
Thanks to the combination of the acquisition and integration of 14 veterinary services and solid organic growth, in FY 2017 this fast-growing veterinary company reported an impressive 51% increase in revenue to $66.9 million. With pet ownership at high levels and the company continuing to grow its footprint, I expect more of the same in FY 2018.
Zenitas Healthcare Ltd (ASX: ZNT)
In FY 2017 this home care and health services company delivered underlying earnings before interest, tax, depreciation, and amortisation of $7 million. This was 27% higher than in FY 2016 and 6.1% higher than its prospectus forecast of $6.6 million. In FY 2018 management expects to deliver organic earnings growth of between 7.5% and 10%, but recent acquisitions will likely lead to much stronger overall growth.
Finally, here are three more top stocks which are growing strongly and could be great options at current prices.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.